| |
Transform the Industry with Your Innovation! Submissions are now open for the Fierce Life Sciences Innovation Awards. Click to submit your entry and learn more about the categories and criteria.
|
|
Today’s Big NewsJul 31, 2024 |
|
September 25-27, 2024 | Philadelphia, PA Join the Fierce Clinical Summit, the premier event for clinical research and trial management. Explore topics in Clinical Operations, Quality, and DCT & Technology. Learn, network, and connect with peers to advance industry standards and innovations in clinical trials. Save up to $500 with Early Bird Rates. Register Now!
|
|
| By Eric Sagonowsky On the heels of game-changing trial results presented at last year's ASH meeting, J&J is introducing what it calls a "foundational frontline therapy" in multiple myeloma and at the same time expanding its already impressive presence in the field. |
|
|
|
By James Waldron GSK has scrapped a phase 2 human papillomavirus vaccine from its pipeline after deciding the asset won’t have best-in-class potential. |
By Darren Incorvaia Since its passage in August 2022, the Inflation Reduction Act has attracted criticism and even derision from biopharma leaders because it gives Medicare the ability to negotiate drug prices. But new studies suggest that fears the IRA will hurt innovation are overblown. |
By Kevin Dunleavy Three-year data from a study of early Alzheimer’s disease patients on Eisai and Biogen’s Leqembi showed that longer-term use provides continued benefits without additional safety concerns. |
|
Sept. 25 - 26, 2024 | San Diego, CA Cutting-edge educational sessions: Gain insights from industry leaders. Early Bird Rate ends August 2nd, Save $400, Register Today!
|
|
By Conor Hale The FDA officially posted its job opening as it looks to replace Jeff Shuren, who is retiring after 15 years as director. The agency’s vacancy will take applications through August 27. |
By Nick Paul Taylor UCB is adding to the subgenre of pharma-backed musical theater, sponsoring a production by an Emmy Award winner and Tony Award nominee that will look at how epilepsy affects a child and her family. |
By Angus Liu The whole RSV vaccine field took a beating when the CDC’s immunization committee doled out a limited recommendation last month. And it’s showing in GSK’s forecast for 2024, just as the company’s Shingrix disappointed. |
By Annalee Armstrong We already know that Takeda is hoping to find a path to the FDA for epilepsy medicine soticlestat despite a phase 3 miss, but the Japanese pharma has now revealed that the clinical trial failure will cost to company just over $140 million. |
By Conor Hale “This is a perfect, classic tuck-in for Stryker,” CEO Kevin Lobo said on an earnings call, with more deals set up for the remainder of the year. |
By Kevin Dunleavy Six months after surviving a patent challenge involving its $3.2 million gene therapy, Sarepta faces a new lawsuit from another gene therapy developer claiming the approved treatment infringes active patents. Sanofi subsidiary Genzyme has filed a complaint in U.S. District Court in Delaware claiming that in producing groundbreaking Duchenne muscular dystrophy treatment Elevidys, Sarepta encroaches on two of its patents involving the manufacture of viral vectors. |
Fierce podcastsDon’t miss an episode |
| | This week on "Podnosis," we dive into the topic of how to improve diversity and equity in dermatology. |
|
|---|
|
|
|
Wednesday, September 11, 2024 | 2pm ET / 11am PT As the drug development landscape rapidly evolves, artificial intelligence (AI) is emerging as a transformative force, fundamentally reshaping processes and enhancing efficiencies. Join us for a deep dive into AI’s significant impact on streamlining clinical project management, revolutionizing the generation of crucial research outputs and accelerating drug discovery. Register now.
|
|
| WhitepaperThis paper explores the costs of setting up a supply chain in Europe for a new biopharma therapy. It outlines key cost drivers & the various levers decision makers can use to affect those costs. Sponsored by: AIM |
| WhitepaperDownload the white paper to learn how this innovative solution can help optimize your mAb production processes. The findings demonstrate the system's robust capability to sustain strong cell growth and high productivity, facilitating a smooth transition from laboratory to production scale. Sponsored by: Thermo Fisher Scientific |
| WhitepaperIn this white paper, Lonza experts delve into the common challenges encountered by ADC developers. They explore new drug product capabilities in relation to cytotoxic drug development and manufacturing, therefore fully completing Lonza’s integrated ADC offering. Further, they discuss how this end-to-end approach can significantly accelerate the timeline to investigational new drug filing and beyond. Read this white paper to learn more. Sponsored by: Lonza |
| WhitepaperThe definitive report on the state of our industry. Readers will gain an understanding of key indicators to monitor, future predictions, and guidance for investors and founders navigating the therapeutic enabling tools and services, healthtech and techbio sectors through 2024 and beyond. Sponsored by: AVANT BIO |
| WhitepaperIn a complex industry like biopharma, being a “Best Practice Organization” (BPO) is essential to success. But what is a BPO & how do you build one? This eBook provides the answers. Sponsored by: Blue Matter, strategic consultants in the life sciences |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
